Familial Partial Lipodystrophy
📧 Sign up to get email alerts when something new happens for Familial Partial Lipodystrophy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Feasibility of Adipose Tissue Triglyceride (TG) Labelling in Familial Partial Lipodystrophy (FPLD)
This clinical trial update describes a feasibility study evaluating labeling of adipose tissue triglycerides in familial partial lipodystrop…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With "Classic" Polycystic Ovary Syndrome (PCOS) [NA]
A clinical trial update from Assistance Publique - Hôpitaux de Paris identifies women with genetically driven severe insulin resistance amon…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Expanded Access Metreleptin Study
Expanded access study of metreleptin for Familial Partial Lipodystrophy sponsored by the University of Michigan. The study status is AVAILAB…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy [Phase 3]
Open-label extension Phase 3 trial evaluating metreleptin in patients with familial partial lipodystrophy, currently recruiting.
-
EMA approval · 2025-11-03EMA Authorised: Myalepta (Metreleptin) — Chiesi Farmaceutici S.p.A.
EMA authorised Myalepta (metreleptin) for lipodystrophy, including familial partial lipodystrophy, with orphan medicine designation; the mar…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-07-31Clinical Trial Update: The Benefits of the Measureof Epicardial Adipose Tissue During Coronary Calcium Assessment of the Refine Cardiovascular Risk Assessment at Reunion Island.
This completed clinical study evaluated whether measuring epicardial adipose tissue alongside coronary calcium scoring improves refinement o…
-
CLINICAL_TRIALS trial_result · 2025-07-02Clinical Trial Update: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) [Phase 2]
A Phase 2 study evaluating REGN4461, a leptin receptor agonist antibody, for familial partial lipodystrophy was terminated with results post…
-
CLINICAL_TRIALS research · 2024-12-05Clinical Trial Update: Low Energy Diet and Familial Partial Lipodystrophy [NA]
A clinical trial is underway to assess the impact of a low energy diet in people with familial partial lipodystrophy and diabetes, and it is…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients [Phase 2]
A Phase 2 trial evaluating obeticholic acid for Familial Partial Lipodystrophy has completed. Results were posted in December 2023.
-
CLINICAL_TRIALS trial_result · 2021-10-18Clinical Trial Update: The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy [Phase 2, Phase 3]
A multi-phase study (Phase 2/3) of volanesorsen in familial partial lipodystrophy was terminated; results were posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-16Clinical Trial Update: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) [Phase 2]
Phase 2 study of AKCEA-ANGPTL3-LRx (ISIS 703802) in familial partial lipodystrophy has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy [Phase 2]
Phase 2 clinical protocol update assessing long-term safety and efficacy of metreleptin in various forms of partial lipodystrophy; study sta…
-
CLINICAL_TRIALS trial_result · 2020-08-17Clinical Trial Update: Study of Gemcabene in Adults With FPLD [Phase 1, Phase 2]
Phase 1/2 trial updates for gemcabene in adults with familial partial lipodystrophy (FPLD) and hypertriglyceridemia have been completed with…
-
FDA approval · 2019-12-13FDA Approved: MYALEPT — Supplemental Application (Chiesi USA, Inc.)
The FDA approved a supplemental application for MYALEPT (metreleptin) filed by Chiesi USA, Inc. This action completes the review of a supple…
-
FDA approval · 2017-12-11FDA Approved: MYALEPT — Supplemental Application (Chiesi USA, Inc.)
The FDA approved a supplemental application for MYALEPT (metreleptin) filed by Chiesi USA, Inc.